In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osteologix AS

Division of Osteologix Holdings PLC
www.osteologix.com

Latest From Osteologix AS

EU suspension for Servier's Protelos on the cards

The EU's pharmacovigilance committee PRAC has recommended to the CHMP that the marketing authorization for Servier's osteoporosis drug Protelos/Osseor (strontium ranelate) be suspended. The product's fate now awaits the CHMP's next meeting on 20-23 January.

Cardiovascular Orthopedics

AmpliPhi makes Philip Young CEO

AmpliPhi Biosciences, a developer of bacteriophage-based antibacterial therapies, has appointed Philip Young president and CEO. Mr Young was formerly president and CEO of Osteologix, and is still on its board of directors. Edward Cappabianca, AmpliPhi's last CEO, has left the company and the board of directors to pursue other interests.

Servier licenses osteoporosis compound from Osteologix

Osteologix, a US speciality pharma company focused on diseases of the bone and joints, has granted Servier Research Group of France an exclusive royalty-bearing licence to its lead product candidate, NB S101 (strontium malonate).

Orthopedics Japan

Recent Financings of Private Companies (07/2006)

Each month, Start-Up presents a comprehensive review of young, private life science companies that have recieved venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Osteologix Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Osteologix Holdings PLC
  • Senior Management
  • Philip J Young, CEO
    Baxter Phillips, III, Senior. Dir., Corporate Dev.
  • Contact Info
  • Osteologix AS
    Phone: (45) 39179730
    Symbion Science Park
    Fruebjergvej 3
    Copenhagen, DK-2100
    Denmark
Advertisement
Advertisement
UsernamePublicRestriction

Register